We use cookies to improve your browsing experience on our website.
Please visit our Privacy Notice for more information about cookies and how we use them. We recommend that you accept the use of cookies for better navigation.

Newsroom

Show
February 01, 2017
ACELITY COMPLETES SALE OF LIFECELL TO ALLERGAN
Acelity L.P. Inc. announced today that it has completed the sale of its regenerative medicine business unit, LifeCell Corporation, to Allergan for $2.9 billion in cash.
SAN ANTONIO, February 1, 2017 – “This milestone marks an important step in our continued evolution of Acelity,” said Joe Woody, Acelity President and Chief Executive Officer. “The completion of this sale to Allergan positions us for ongoing success by allowing additional focus in our areas of long-standing expertise. We look forward to fully dedicating our resources to strengthening our leading advanced wound therapies business and increasing our global growth opportunities in that space.”
 
Under the terms of the transaction, Allergan will acquire LifeCell Corporation, the subsidiary from which the Acelity regenerative medicine unit is operated, and each of LifeCell’s subsidiaries. LifeCell’s industry-leading regenerative medicine and reconstructive surgery portfolio will be combined with Allergan’s leading portfolio of medical aesthetics, breast implants and tissue expanders, enhancing the potential for continued long-term growth of the LifeCell portfolio. 
 
Buddy Gumina, Chairman of the Acelity Board of Directors added: “We are incredibly excited to continue to support Acelity as it further expands its advanced wound therapy solutions, both through the introduction of innovative products and through targeted acquisitions.”
 
Acelity will use the majority of the proceeds from the sale, together with proceeds from new senior secured credit facilities and cash on hand, to repay all of the outstanding borrowings under the existing senior secured credit facilities and redeem all of the outstanding aggregate principal amounts of the 9.625% Second Lien Senior Secured Notes due 2021 and 12.5% Senior Notes due 2019, each issued by Acelity’s wholly-owned subsidiaries, Kinetic Concepts, Inc. and KCI USA, Inc., and pay applicable premiums and related fees and expenses.

About Acelity
Acelity L.P. Inc. and its subsidiaries are a global advanced wound care company that leverages the strengths of Kinetic Concepts, Inc. and Systagenix Wound Management, Limited. Available in more than 80 countries, the innovative and complementary ACELITY™ product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs nearly 5,000 people around the world.

For more information, contact: 

 

Maggie Fairchild

Corporate Communications

Phone: +1-210-330-2667

Email: maggie.fairchild@acelity.com

 

Jathan Tucker,

Investor Relations

Phone: +1-210-255-6817

Email: jathan.tucker@acelity.com